Literature DB >> 15623659

Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier.

Rongbao Zhao1, Shrikanta Chattopadhyay, Marie Hanscom, I David Goldman.   

Abstract

Prior studies from this laboratory documented the prevalence of methotrexate (MTX) transport activity with a low pH optimum in human solid tumor cell lines. In HeLa cells, this low pH activity has high affinity for pemetrexed [PMX (Alimta)] and is reduced folate carrier (RFC)-independent because it is not diminished in a RFC-null subline (R5). R5 cells also have residual transport activity, with high specificity for PMX, at neutral pH. In the current study, a R5 subline, R1, was selected under MTX selective pressure at a modest reduction in pH. There was markedly decreased MTX and PMX transport at both pH 5.5 and pH 7.4. When MTX was removed, there was a slow return of transport activity, and when MTX was added back, there was loss of transport at both pH values within 8 weeks. In R1 cells, there was a marked decrease in accumulation of PMX, MTX, and folic acid along with a decrease in growth inhibition by these and other antifolates that require a facilitative process to gain entry into cells. These data demonstrate that (i) RFC-independent transport in HeLa cells at low and neutral pH contributes to antifolate activity (in particular, to PMX activity) and can be diminished by antifolate selective pressure and (ii) the loss of these activities results in marked resistance to PMX, an agent for which there is little or no loss of activity when transport mediated by RFC is abolished. These observations suggest that transport activity in RFC-null HeLa R5 cells at neutral and low pH may reflect the same carrier-mediated process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15623659     DOI: 10.1158/1078-0432.CCR-04-0932

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.

Authors:  Michele Visentin; Ersin Selcuk Unal; Rongbao Zhao; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-24       Impact factor: 3.333

2.  Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis.

Authors:  Rongbao Zhao; Michele Visentin; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-07       Impact factor: 3.333

3.  Residues in the eighth transmembrane domain of the proton-coupled folate transporter (SLC46A1) play an important role in defining the aqueous translocation pathway and in folate substrate binding.

Authors:  Srinivas Aluri; Rongbao Zhao; Andras Fiser; I David Goldman
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-08-09       Impact factor: 3.747

Review 4.  Mechanisms of membrane transport of folates into cells and across epithelia.

Authors:  Rongbao Zhao; Ndeye Diop-Bove; Michele Visentin; I David Goldman
Journal:  Annu Rev Nutr       Date:  2011-08-21       Impact factor: 11.848

5.  Random mutagenesis of the proton-coupled folate transporter (SLC46A1), clustering of mutations, and the bases for associated losses of function.

Authors:  Rongbao Zhao; Daniel Sanghoon Shin; Ndeye Diop-Bove; Channa Gila Ovits; I David Goldman
Journal:  J Biol Chem       Date:  2011-05-20       Impact factor: 5.157

6.  A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis.

Authors:  Rongbao Zhao; Sang Hee Min; Yanhua Wang; Estela Campanella; Philip S Low; I David Goldman
Journal:  J Biol Chem       Date:  2008-12-11       Impact factor: 5.157

7.  Identification of the minimal functional unit of the homo-oligomeric human reduced folate carrier.

Authors:  Zhanjun Hou; Christina Cherian; Joseph Drews; Jianmei Wu; Larry H Matherly
Journal:  J Biol Chem       Date:  2009-12-17       Impact factor: 5.157

8.  Substrate-specific binding and conformational changes involving Ser313 and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking.

Authors:  Zhanjun Hou; Jianmei Wu; Jun Ye; Christina Cherian; Larry H Matherly
Journal:  Biochem J       Date:  2010-09-01       Impact factor: 3.857

9.  Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.

Authors:  Sita Kugel Desmoulin; Lei Wang; Lisa Polin; Kathryn White; Juiwanna Kushner; Mark Stout; Zhanjun Hou; Christina Cherian; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2012-06-26       Impact factor: 4.436

10.  The functional roles of the His247 and His281 residues in folate and proton translocation mediated by the human proton-coupled folate transporter SLC46A1.

Authors:  Ersin Selcuk Unal; Rongbao Zhao; Min-Hwang Chang; Andras Fiser; Michael F Romero; I David Goldman
Journal:  J Biol Chem       Date:  2009-04-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.